Literature DB >> 23940223

Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.

Francesco Gelsomino1, Francesco Agustoni, Monica Niger, Marika Valota, Eva R Haspinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23940223     DOI： 10.1200/JCO.2013.50.2617

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.

Authors:  Feng Zhang; You Yu; Lina Xing; Min Chen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.

Authors:  L J Fallowfield; S L Catt; S F May; L Matthews; V M Shilling; R Simcock; S Westwell; V A Jenkins
Journal:  Support Care Cancer       Date:  2016-09-13       Impact factor: 3.603

Review 3.  Molecular pathways and therapeutic targets in lung cancer.

Authors:  Emma Shtivelman; Thomas Hensing; George R Simon; Phillip A Dennis; Gregory A Otterson; Raphael Bueno; Ravi Salgia
Journal:  Oncotarget       Date:  2014-03-30

4.  Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.

Authors:  Rajasekhara Reddy Katreddy; Lakshmi Reddy Bollu; Fei Su; Na Xian; Shivangi Srivastava; Rintu Thomas; Yubing Dai; Bing Wu; Yunlu Xu; Michael A Rea; James M Briggs; Qingyuan Zhang; Xiongbin Lu; Gangxiong Huang; Zhang Weihua
Journal:  Oncogenesis       Date:  2018-01-23       Impact factor: 7.485

5.  Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.

Authors:  Nan Yao; Chen-Ran Wang; Ming-Qun Liu; Ying-Jie Li; Wei-Min Chen; Zheng-Qiu Li; Qi Qi; Jin-Jian Lu; Chun-Lin Fan; Min-Feng Chen; Ming Qi; Xiao-Bo Li; Jian Hong; Dong-Mei Zhang; Wen-Cai Ye
Journal:  Signal Transduct Target Ther       Date:  2020-10-09

6.  Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.

Authors:  Chan Shen; Rolfy A Perez Holguin; Eric Schaefer; Shouhao Zhou; Chandra P Belani; Patrick C Ma; Michael F Reed
Journal:  BMC Health Serv Res       Date:  2022-04-09       Impact factor: 2.655

7.  The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Authors:  Donald L Smith; Jaime Acquaviva; Manuel Sequeira; John-Paul Jimenez; Chaohua Zhang; Jim Sang; Richard C Bates; David A Proia
Journal:  Target Oncol       Date:  2014-08-01       Impact factor: 4.493

8.  Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Authors:  Man Kit Siu; Wassim Abou-Kheir; Juan Juan Yin; Yung-Sheng Chang; Ben Barrett; Florent Suau; Orla Casey; Wei-Yu Chen; Lei Fang; Paul Hynes; Yao-Yu Hsieh; Yen-Nien Liu; Jiaoti Huang; Kathleen Kelly
Journal:  Oncotarget       Date:  2014-06-15

9.  Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Authors:  Rintu Thomas; Zhang Weihua
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.